Development of a human IgG4 bispecific antibody for dual targeting of interleukin-4 (IL-4) and interleukin-13 (IL-13) cytokines.
about
Predicting pharmacokinetic profile of therapeutic antibodies after iv injection from only the data after sc injection in cynomolgus monkey.Role of periostin, FENO, IL-13, lebrikzumab, other IL-13 antagonist and dual IL-4/IL-13 antagonist in asthma.Novel targeted therapies for eosinophil-associated diseases and allergyA two-in-one antibody engineered from a humanized interleukin 4 antibody through mutation in heavy chain complementarity-determining regions.Optimizing antibody expression by using the naturally occurring framework diversity in a live bacterial antibody display systemCytokine Networks and T-Cell Subsets in Inflammatory Bowel DiseasesEfficient production of bispecific IgG of different isotypes and species of origin in single mammalian cells.Immunological aspects of rabies: a literature review.The use of CrossMAb technology for the generation of bi- and multispecific antibodies.Bifunctional Drugs for the Treatment of Respiratory Diseases.A fully humanized IgG-like bispecific antibody for effective dual targeting of CXCR3 and CCR6.Immuno-evasive tactics by schistosomes identify an effective allergy preventative.The making of bispecific antibodiesDevelopment of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidity.Improved assembly of bispecific antibodies from knob and hole half-antibodies.Immunoglobulin G; structure and functional implications of different subclass modifications in initiation and resolution of allergy.Development of a novel affinity chromatography resin for platform purification of bispecific antibodies with modified protein a binding avidity.Preclinical pharmacokinetic characterization of an adipose tissue-targeting monoclonal antibody in obese and non-obese animals.Bispecific antibodies in cancer immunotherapy.Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies
P2860
Q31091923-35B37322-A796-4B39-A488-8953C17AA1F9Q34388348-E3D7D09C-7DCE-4ECA-9647-12995C0450E8Q34444620-58FB20CB-593F-4239-9256-7460E2F73622Q35117636-982BE305-03C0-4F29-AAE5-E4D4A1940DEFQ35859635-8B42FDB0-E160-4B2F-AC1E-7006984F377DQ36818290-0612C426-DD8B-4A57-B289-D40097DA43A1Q37631316-D54E3DDA-BB58-481C-90D2-7F5EF78ACAC2Q38654706-65BEB05D-C6CB-43F8-BF16-CD6693C43B6CQ38861238-1CFD9D65-DADD-4CAF-B610-252307587DF8Q38992596-F55C42EF-4375-43F8-B644-C81C458A951FQ40066330-9D6F3263-4537-4718-9670-9E997194A5DAQ41373939-9665D8A9-7913-4A8D-9214-F001177A0000Q42323236-2521E792-7DB3-49A3-8093-96184521FC84Q42392973-274102BC-DC09-4DEC-ABE6-D2CE209F31F1Q46711768-028A66E0-A5E1-4D9B-9447-66641508BAA8Q48256010-25562AD4-E268-403A-84B0-B756558700B7Q49718154-64CCDFA5-7AC2-40FE-B504-F314C52699AEQ50140611-7E35F31F-E951-4B5B-9E07-B79AB7D4F740Q51309023-919E09F7-5BF8-4A13-ACBF-05DCB26B4EC8Q58724935-3780F3C7-CF07-41A7-B7E5-5AA1BAEE2106
P2860
Development of a human IgG4 bispecific antibody for dual targeting of interleukin-4 (IL-4) and interleukin-13 (IL-13) cytokines.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Development of a human IgG4 bi ...... erleukin-13 (IL-13) cytokines.
@en
Development of a human IgG4 bispecific antibody for dual targeting of interleukin-4
@nl
type
label
Development of a human IgG4 bi ...... erleukin-13 (IL-13) cytokines.
@en
Development of a human IgG4 bispecific antibody for dual targeting of interleukin-4
@nl
prefLabel
Development of a human IgG4 bi ...... erleukin-13 (IL-13) cytokines.
@en
Development of a human IgG4 bispecific antibody for dual targeting of interleukin-4
@nl
P2093
P2860
P356
P1476
Development of a human IgG4 bi ...... erleukin-13 (IL-13) cytokines.
@en
P2093
Christoph Spiess
Dorothea Reilly
Enzo Palma
Eric Stefanich
Gerald Nakamura
Germaine Fuh
Glen Giese
Heleen Scheerens
Hongbin Liu
J Michael Elliott
P2860
P304
26583-26593
P356
10.1074/JBC.M113.480483
P407
P577
2013-07-23T00:00:00Z